1. Home
  2. FISV vs NTRA Comparison

FISV vs NTRA Comparison

Compare FISV & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fiserv Inc.

FISV

Fiserv Inc.

N/A

Current Price

$60.37

Market Cap

34.1B

Sector

Real Estate

ML Signal

N/A

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$198.91

Market Cap

32.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FISV
NTRA
Founded
1984
2003
Country
United States
United States
Employees
38000
N/A
Industry
Real Estate
Medical Specialities
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.1B
32.9B
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
FISV
NTRA
Price
$60.37
$198.91
Analyst Decision
Buy
Strong Buy
Analyst Count
28
14
Target Price
$146.17
$253.79
AVG Volume (30 Days)
8.6M
967.7K
Earning Date
01-01-0001
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
0.65
EPS
N/A
N/A
Revenue
N/A
$210,939,000.00
Revenue This Year
N/A
$34.18
Revenue Next Year
$4.31
$16.69
P/E Ratio
$9.94
N/A
Revenue Growth
N/A
N/A
52 Week Low
$57.79
$125.38
52 Week High
$70.41
$256.36

Technical Indicators

Market Signals
Indicator
FISV
NTRA
Relative Strength Index (RSI) 45.77 36.71
Support Level $57.79 $195.46
Resistance Level $68.87 $251.09
Average True Range (ATR) 2.46 7.68
MACD 0.21 0.23
Stochastic Oscillator 41.69 22.27

Price Performance

Historical Comparison
FISV
NTRA

About FISV Fiserv Inc.

Fiserv is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Following its 2019 merger with First Data, Fiserv also provides payment processing services to merchants. About 10% of the company's revenue is generated internationally.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: